- The ability to multiplex hundreds of samples in one sequencing run, which reduces sequencing costs for high-throughput labs.
- The ability to remove sample contamination as a result of index hopping from reads.
- Better error correction to detect variants with low allele frequencies (particularly important in cancer applications where the samples are often of varying tumor purity).
- The option to purchase Solid Phase Reversible Immobilization (SPRI) beads and streptavidin beads as part of a complete kit.
Press Release
Agilent Introduces New Cutting-Edge SureSelect DNA Kit
Enhanced performance and flexibility to power cancer and genetics research
Agilent Technologies Inc. (NYSE: A) today introduced a new product designed to address key challenges that laboratories encounter when preparing DNA sequencing libraries for their research. The new Agilent SureSelect XT HS2 DNA Kit represents the state-of-the-art in library preparation and target enrichment, offering researchers a complete solution that allows them to choose workflow options that best suit their needs.
Advantages of the new kit include: